Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Neratinib Maleate Patent Expiration

Neratinib Maleate is used for treating early-stage and advanced HER2-positive breast cancer. It was first introduced by Puma Biotechnology Inc in its drug Nerlynx on Jul 17, 2017.


Neratinib Maleate Patents

Given below is the list of patents protecting Neratinib Maleate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nerlynx US10035788 Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct 15, 2028 Puma Biotech
Nerlynx US6288082 Substituted 3-cyanoquinolines Sep 24, 2019

(Expired)

 Puma Biotech
Nerlynx US7399865 Protein tyrosine kinase enzyme inhibitors Dec 29, 2030 Puma Biotech
Nerlynx US7982043 Protein tyrosine kinase enzyme inhibitors Oct 08, 2025 Puma Biotech
Nerlynx US8518446 Coated tablet formulations and uses thereof Nov 20, 2030 Puma Biotech
Nerlynx US8669273 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Jul 18, 2031 Puma Biotech
Nerlynx US8790708 Coated tablet formulations and uses thereof Nov 05, 2030 Puma Biotech
Nerlynx US9139558 Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct 15, 2028 Puma Biotech
Nerlynx US9211291 Treatment regimen utilizing neratinib for breast cancer Mar 24, 2030 Puma Biotech
Nerlynx US9265784 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Aug 04, 2029 Puma Biotech
Nerlynx US9630946 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof Oct 15, 2028 Puma Biotech


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳